Fig 7.

In vitro and in vivo evaluation of lamivudine activity against GPA- EBOV (A) Huh 7 cells were pre-treated with toremifene citrate or lamivudine for 1 h. Cells were then inoculated at a multiplicity of infection (MOI) of 0.1 for 48 h. Antiviral activity is shown in blue and cytotoxicity is shown in red. The experiment was run on duplicate plates with triplicate wells per dose (mean ± SD; n = 3). Representative graphs from 2 independent experiments are shown. (B) Percent survival and weight loss of lamivudine-treated guinea pigs infected with guinea pig-adapted-Ebola virus/Mayinga variant (GPA-EBOV/May). Two groups of guinea pigs (n = 6) received oral lamivudine at 20 mg/kg or 60 mg/kg daily from d 3 pre-exposure to d 9 post-exposure. In parallel, the mock group (n = 7) was treated with water. All animals were challenged intraperitoneally (IP) with approximately 1300 pfu of GPA-EBOV/May on d 0.